Interpace Biosciences Inc
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test for the diagnosis of pancreaticobiliary cancers using its proprietary PathFinderTG platform; PanDNA, a molecular only version of PancraGEN; and ThyGeNEXT, an … Read more
Interpace Biosciences Inc (IDXG) - Total Assets
Latest total assets as of September 2025: $12.04 Million USD
Based on the latest financial reports, Interpace Biosciences Inc (IDXG) holds total assets worth $12.04 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Interpace Biosciences Inc - Total Assets Trend (2000–2024)
This chart illustrates how Interpace Biosciences Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Interpace Biosciences Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Interpace Biosciences Inc's total assets of $12.04 Million consist of 79.6% current assets and 20.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 9.9% |
| Accounts Receivable | $8.54 Million | 57.8% |
| Inventory | $1.21 Million | 8.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2000–2024)
This chart illustrates how Interpace Biosciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Interpace Biosciences Inc's current assets represent 79.6% of total assets in 2024, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 9.9% of total assets in 2024, down from 40.3% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 2.0% in 2000.
- Asset Diversification: The largest asset category is accounts receivable at 57.8% of total assets.
Interpace Biosciences Inc Competitors by Total Assets
Key competitors of Interpace Biosciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF
|
USA | $4.51 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
NSN Co. Ltd
KQ:031860
|
Korea | ₩60.96 Billion |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
Interpace Biosciences Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Interpace Biosciences Inc generates 3.17x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Interpace Biosciences Inc generates $ 45.31 in net profit.
Interpace Biosciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.54 | 0.59 | 1.13 |
| Quick Ratio | 1.35 | 0.53 | 1.00 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.19 Million | $ -7.66 Million | $ 2.03 Million |
Interpace Biosciences Inc - Advanced Valuation Insights
This section examines the relationship between Interpace Biosciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 10.04 |
| Latest Market Cap to Assets Ratio | 0.13 |
| Asset Growth Rate (YoY) | 13.6% |
| Total Assets | $14.79 Million |
| Market Capitalization | $1.85 Million USD |
Valuation Analysis
Below Book Valuation: The market values Interpace Biosciences Inc's assets below their book value (0.13 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Interpace Biosciences Inc's assets grew by 13.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Interpace Biosciences Inc (2000–2024)
The table below shows the annual total assets of Interpace Biosciences Inc from 2000 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $14.79 Million | +13.60% |
| 2023-12-31 | $13.02 Million | -18.51% |
| 2022-12-31 | $15.98 Million | -58.42% |
| 2021-12-31 | $38.43 Million | -15.88% |
| 2020-12-31 | $45.68 Million | -11.37% |
| 2019-12-31 | $51.54 Million | +6.40% |
| 2018-12-31 | $48.44 Million | -9.62% |
| 2017-12-31 | $53.60 Million | +28.29% |
| 2016-12-31 | $41.78 Million | -38.30% |
| 2015-12-31 | $67.71 Million | -41.58% |
| 2014-12-31 | $115.91 Million | +67.82% |
| 2013-12-31 | $69.06 Million | -11.96% |
| 2012-12-31 | $78.45 Million | -30.81% |
| 2011-12-31 | $113.38 Million | -8.85% |
| 2010-12-31 | $124.39 Million | +13.31% |
| 2009-12-31 | $109.78 Million | -26.34% |
| 2008-12-31 | $149.04 Million | -17.00% |
| 2007-12-31 | $179.55 Million | -10.95% |
| 2006-12-31 | $201.64 Million | +0.66% |
| 2005-12-31 | $200.31 Million | -10.86% |
| 2004-12-31 | $224.71 Million | +2.31% |
| 2003-12-31 | $219.62 Million | +15.02% |
| 2002-12-31 | $190.94 Million | -36.92% |
| 2001-12-31 | $302.67 Million | +12.01% |
| 2000-12-31 | $270.23 Million | -- |